Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 4. CKD-581 activates tumor suppressors and reduces the expression of BCL-2 family in MM. (A) MM.1S and RPMI8226 cells were treated with 300 nM CKD-581 according to time course. And total cell lysates were subjected to immunoblottings for Ser15-phosphorylated p53, p53 and p21. (B) MM.1S and RPMI8226 cells were treated with CKD-581 or SAHA for 24 h. BCL-2 and BCL-xL were detected by immunoblottings. Data represent mean ± SEM (significant vs. control; *p<0.05, **p<0.01, ***p<0.001). C, control; S, 1000 nM SAHA.
Biomolecules & Therapeutics 2022;30:435~446 https://doi.org/10.4062/biomolther.2022.022
© Biomolecules & Therapeutics